NCT07543055 2026-04-21
A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread
Regeneron Pharmaceuticals
Phase 1 Not yet recruiting
Regeneron Pharmaceuticals
National Cancer Institute (NCI)
Yonsei University
Amgen
Gan & Lee Pharmaceuticals.
Instituto do Cancer do Estado de São Paulo
Hangzhou DAC Biotechnology Co., Ltd.
Peter MacCallum Cancer Centre, Australia
Geode Therapeutics Inc.
Danatlas Pharmaceuticals Co., Ltd